Global Hormonal Therapy for Cancer Market Research Report 2026(Status and Outlook)

May 2026 | 154 pages | ID: GB336B0A6540EN
Bosson Research

US$ 3,200.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Hormonal therapy for cancer is a class of treatments that modulate endocrine signaling to inhibit or block the growth of hormone-dependent tumors. Approaches include suppressing hormone synthesis, blocking hormone receptors, and using receptor modulators; these are widely applied in estrogen- or androgen-sensitive cancers such as breast and prostate cancer. Hormonal therapy may be used as adjuvant treatment in early-stage disease to reduce recurrence risk, and as long-term maintenance or symptom-control therapy in advanced or metastatic settings. Recent advances in molecular subtyping, companion diagnostics, and combination regimens have elevated the role of hormonal therapies within precision oncology, prompting pharmaceutical firms to invest more in drug optimization, label expansion, and co-development with other targeted or immune agents—creating fresh commercialization and value-chain integration opportunities.Hormonal therapy for cancer is at an inflection point, shifting from traditional mono-therapy maintenance to precision-guided and combination strategies. Annual reports from major pharmaceutical firms emphasize that label expansion, companion diagnostics, and combinations with novel small molecules or biologics can convert long-standing hormonal platforms into higher-value clinical solutions. Regulators’ increasing focus on biomarker-driven indications and combination regimens—including expedited review pathways in some jurisdictions—provides policy support for faster clinical adoption. Meanwhile, capital markets and M&A activity favor platform companies with expandable treatment lines and robust clinical evidence, concentrating resources on projects with combination potential and diagnostic capabilities, thereby accelerating innovation and commercialization.Opportunities come with material uncertainty. Combination regimens and indication expansions require lengthy clinical validation and complex regulatory pathways, increasing upfront investment and time to market. Annual reports and regulatory notices highlight risks from patent expiries, generic competition, and reimbursement policy shifts that can disrupt established revenue models. Furthermore, commercialization of companion diagnostics demands cross-sector collaboration (pharma, diagnostics, clinical services); delays or mismatches in any link can slow overall launch. Thus, while pursuing efficacy and differentiation, firms must concurrently manage R&D, compliance, and supply-chain pressures. Downstream demand is evolving from outcome-centric to continuity-and-connectivity-centric. Clinicians now evaluate hormonal regimens not only for efficacy and safety, but also for long-term management convenience and integration with imaging and molecular testing. Pharma partnerships with clinical research organizations and diagnostics firms on companion assays and real-world evidence generation are intensifying, shifting commercial models from pure product supply toward service-oriented platforms. For marketing and investor audiences, companies that can demonstrate an end-to-end value chain—from drug to diagnostic to follow-up—are more likely to capture procurement and capital attention. The upstream ecosystem for hormonal therapies and related combination products includes active pharmaceutical ingredients (APIs), advanced formulation excipients and delivery technologies, and molecular reagents for companion diagnostics. Annual reports indicate that global supply availability, consistent quality, and regulatory compliance of key APIs and diagnostic reagents critically impact the ability to scale production and enter new markets rapidly. In the face of geopolitical and trade policy volatility, firms that achieve regionalized sourcing or upstream self-sufficiency will realize durable advantages in cost, delivery reliability, and compliance—foundations that underpin downstream commercialization.

The global Hormonal Therapy for Cancer market size was estimated at USD 16521.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 13.20% during the forecast period.

This report offers a comprehensive and in-depth analysis of the global Hormonal Therapy for Cancer market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.

The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.

A significant focus of this report lies in the competitive landscape of the global Hormonal Therapy for Cancer market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.

In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Hormonal Therapy for Cancer market.

Global Hormonal Therapy for Cancer Market: Market Segmentation Analysis

This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.

A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.

Key Company

  • GlaxoSmithKline
  • Jiangsu Haosen
  • Sun Pharmaceutical
  • Hengrui Medical
  • Dr Reddy's Laboratories
  • Astellas Pharma
  • Sumitomo Pharma
  • Johnson & Johnson
  • Bayer AG
  • Pfizer
  • AstraZeneca
  • Novartis
  • Ferring Pharmaceuticals
  • Myovant Sciences

Market Segmentation (by Type)

  • Tablet
  • Capsule
  • Injection
  • Others

Market Segmentation (by Application)

  • Hospital
  • Retail Pharmacy
  • Other

Geographic Segmentation

  • North America (USA, Canada, Mexico)
  • Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
  • Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
  • South America (Brazil, Argentina, Columbia, Rest of South America)
  • The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

  • Industry drivers, restraints, and opportunities covered in the study
  • Neutral perspective on the market performance
  • Recent industry trends and developments
  • Competitive landscape & strategies of key players
  • Potential & niche segments and regions exhibiting promising growth covered
  • Historical, current, and projected market size, in terms of value
  • In-depth analysis of the Hormonal Therapy for Cancer Market

Overview of the regional outlook of the Hormonal Therapy for Cancer Market:

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Hormonal Therapy for Cancer Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 shares the main producing countries of Hormonal Therapy for Cancer, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.

Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.

Chapter 13 is the main points and conclusions of the report.

Key Reasons to Buy this Report:

  • Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
  • This enables you to anticipate market changes to remain ahead of your competitors
  • You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
  • The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
  • Provision of market value data for each segment and sub-segment
  • Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
  • Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
  • Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
  • Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
  • The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
  • Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
  • Provides insight into the market through Value Chain
  • Market dynamics scenario, along with growth opportunities of the market in the years to come
  • 6-month post-sales analyst support
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

1.1 Market Definition and Statistical Scope of Hormonal Therapy for Cancer
1.2 Key Market Segments
  1.2.1 Hormonal Therapy for Cancer Segment by Type
  1.2.2 Hormonal Therapy for Cancer Segment by Application
1.3 Methodology & Sources of Information
  1.3.1 Research Methodology
  1.3.2 Research Process
  1.3.3 Market Breakdown and Data Triangulation
  1.3.4 Base Year
  1.3.5 Report Assumptions & Caveats

2 HORMONAL THERAPY FOR CANCER MARKET OVERVIEW

2.1 Global Market Overview
  2.1.1 Global Hormonal Therapy for Cancer Market Size (M USD) Estimates and Forecasts (2020-2035)
  2.1.2 Global Hormonal Therapy for Cancer Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region

3 HORMONAL THERAPY FOR CANCER MARKET COMPETITIVE LANDSCAPE

3.1 Company Assessment Quadrant
3.2 Global Hormonal Therapy for Cancer Product Life Cycle
3.3 Global Hormonal Therapy for Cancer Sales by Manufacturers (2020-2025)
3.4 Global Hormonal Therapy for Cancer Revenue Market Share by Manufacturers (2020-2025)
3.5 Hormonal Therapy for Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Hormonal Therapy for Cancer Average Price by Manufacturers (2020-2025)
3.7 Manufacturers’ Manufacturing Sites, Areas Served, and Product Types
3.8 Hormonal Therapy for Cancer Market Competitive Situation and Trends
  3.8.1 Hormonal Therapy for Cancer Market Concentration Rate
  3.8.2 Global 5 and 10 Largest Hormonal Therapy for Cancer Players Market Share by Revenue
  3.8.3 Mergers & Acquisitions, Expansion

4 HORMONAL THERAPY FOR CANCER INDUSTRY CHAIN ANALYSIS

4.1 Hormonal Therapy for Cancer Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF HORMONAL THERAPY FOR CANCER MARKET

5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
  5.4.1 New Product Developments
  5.4.2 Mergers & Acquisitions
  5.4.3 Expansions
  5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
  5.5.1 Industry Policies Analysis
  5.5.2 Economic Environment Analysis
  5.5.3 Social Environment Analysis
  5.5.4 Technological Environment Analysis
5.6 Global Hormonal Therapy for Cancer Market Porter's Five Forces Analysis
  5.6.1 Global Trade Frictions
  5.6.2 U.S. Tariff Policy – April 2025
  5.6.3 Global Trade Frictions and Their Impacts to Hormonal Therapy for Cancer Market
5.7 ESG Ratings of Leading Companies

6 HORMONAL THERAPY FOR CANCER MARKET SEGMENTATION BY TYPE

6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Hormonal Therapy for Cancer Sales Market Share by Type (2020-2025)
6.3 Global Hormonal Therapy for Cancer Market Size by Type (2020-2025)
6.4 Global Hormonal Therapy for Cancer Price by Type (2020-2025)

7 HORMONAL THERAPY FOR CANCER MARKET SEGMENTATION BY APPLICATION

7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Hormonal Therapy for Cancer Market Sales by Application (2020-2025)
7.3 Global Hormonal Therapy for Cancer Market Size (M USD) by Application (2020-2025)
7.4 Global Hormonal Therapy for Cancer Sales Growth Rate by Application (2020-2025)

8 HORMONAL THERAPY FOR CANCER MARKET SALES BY REGION

8.1 Global Hormonal Therapy for Cancer Sales by Region
  8.1.1 Global Hormonal Therapy for Cancer Sales by Region
  8.1.2 Global Hormonal Therapy for Cancer Sales Market Share by Region
8.2 Global Hormonal Therapy for Cancer Market Size by Region
  8.2.1 Global Hormonal Therapy for Cancer Market Size by Region
  8.2.2 Global Hormonal Therapy for Cancer Market Size by Region
8.3 North America
  8.3.1 North America Hormonal Therapy for Cancer Sales by Country
  8.3.2 North America Hormonal Therapy for Cancer Market Size by Country
  8.3.3 U.S. Market Overview
  8.3.4 Canada Market Overview
  8.3.5 Mexico Market Overview
8.4 Europe
  8.4.1 Europe Hormonal Therapy for Cancer Sales by Country
  8.4.2 Europe Hormonal Therapy for Cancer Market Size by Country
  8.4.3 Germany Market Overview
  8.4.4 France Market Overview
  8.4.5 U.K. Market Overview
  8.4.6 Italy Market Overview
  8.4.7 Spain Market Overview
8.5 Asia Pacific
  8.5.1 Asia Pacific Hormonal Therapy for Cancer Sales by Region
  8.5.2 Asia Pacific Hormonal Therapy for Cancer Market Size by Region
  8.5.3 China Market Overview
  8.5.4 Japan Market Overview
  8.5.5 South Korea Market Overview
  8.5.6 India Market Overview
  8.5.7 Southeast Asia Market Overview
8.6 South America
  8.6.1 South America Hormonal Therapy for Cancer Sales by Country
  8.6.2 South America Hormonal Therapy for Cancer Market Size by Country
  8.6.3 Brazil Market Overview
  8.6.4 Argentina Market Overview
  8.6.5 Columbia Market Overview
8.7 Middle East and Africa
  8.7.1 Middle East and Africa Hormonal Therapy for Cancer Sales by Region
  8.7.2 Middle East and Africa Hormonal Therapy for Cancer Market Size by Region
  8.7.3 Saudi Arabia Market Overview
  8.7.4 UAE Market Overview
  8.7.5 Egypt Market Overview
  8.7.6 Nigeria Market Overview
  8.7.7 South Africa Market Overview

9 HORMONAL THERAPY FOR CANCER MARKET PRODUCTION BY REGION

9.1 Global Production of Hormonal Therapy for Cancer by Region(2020-2025)
9.2 Global Hormonal Therapy for Cancer Revenue Market Share by Region (2020-2025)
9.3 Global Hormonal Therapy for Cancer Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Hormonal Therapy for Cancer Production
  9.4.1 North America Hormonal Therapy for Cancer Production Growth Rate (2020-2025)
  9.4.2 North America Hormonal Therapy for Cancer Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Hormonal Therapy for Cancer Production
  9.5.1 Europe Hormonal Therapy for Cancer Production Growth Rate (2020-2025)
  9.5.2 Europe Hormonal Therapy for Cancer Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Hormonal Therapy for Cancer Production (2020-2025)
  9.6.1 Japan Hormonal Therapy for Cancer Production Growth Rate (2020-2025)
  9.6.2 Japan Hormonal Therapy for Cancer Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Hormonal Therapy for Cancer Production (2020-2025)
  9.7.1 China Hormonal Therapy for Cancer Production Growth Rate (2020-2025)
  9.7.2 China Hormonal Therapy for Cancer Production, Revenue, Price and Gross Margin (2020-2025)

10 KEY COMPANIES PROFILE

10.1 GlaxoSmithKline
  10.1.1 GlaxoSmithKline Basic Information
  10.1.2 GlaxoSmithKline Hormonal Therapy for Cancer Product Overview
  10.1.3 GlaxoSmithKline Hormonal Therapy for Cancer Product Market Performance
  10.1.4 GlaxoSmithKline Business Overview
  10.1.5 GlaxoSmithKline SWOT Analysis
  10.1.6 GlaxoSmithKline Recent Developments
10.2 Jiangsu Haosen
  10.2.1 Jiangsu Haosen Basic Information
  10.2.2 Jiangsu Haosen Hormonal Therapy for Cancer Product Overview
  10.2.3 Jiangsu Haosen Hormonal Therapy for Cancer Product Market Performance
  10.2.4 Jiangsu Haosen Business Overview
  10.2.5 Jiangsu Haosen SWOT Analysis
  10.2.6 Jiangsu Haosen Recent Developments
10.3 Sun Pharmaceutical
  10.3.1 Sun Pharmaceutical Basic Information
  10.3.2 Sun Pharmaceutical Hormonal Therapy for Cancer Product Overview
  10.3.3 Sun Pharmaceutical Hormonal Therapy for Cancer Product Market Performance
  10.3.4 Sun Pharmaceutical Business Overview
  10.3.5 Sun Pharmaceutical SWOT Analysis
  10.3.6 Sun Pharmaceutical Recent Developments
10.4 Hengrui Medical
  10.4.1 Hengrui Medical Basic Information
  10.4.2 Hengrui Medical Hormonal Therapy for Cancer Product Overview
  10.4.3 Hengrui Medical Hormonal Therapy for Cancer Product Market Performance
  10.4.4 Hengrui Medical Business Overview
  10.4.5 Hengrui Medical Recent Developments
10.5 Dr Reddy's Laboratories
  10.5.1 Dr Reddy's Laboratories Basic Information
  10.5.2 Dr Reddy's Laboratories Hormonal Therapy for Cancer Product Overview
  10.5.3 Dr Reddy's Laboratories Hormonal Therapy for Cancer Product Market Performance
  10.5.4 Dr Reddy's Laboratories Business Overview
  10.5.5 Dr Reddy's Laboratories Recent Developments
10.6 Astellas Pharma
  10.6.1 Astellas Pharma Basic Information
  10.6.2 Astellas Pharma Hormonal Therapy for Cancer Product Overview
  10.6.3 Astellas Pharma Hormonal Therapy for Cancer Product Market Performance
  10.6.4 Astellas Pharma Business Overview
  10.6.5 Astellas Pharma Recent Developments
10.7 Sumitomo Pharma
  10.7.1 Sumitomo Pharma Basic Information
  10.7.2 Sumitomo Pharma Hormonal Therapy for Cancer Product Overview
  10.7.3 Sumitomo Pharma Hormonal Therapy for Cancer Product Market Performance
  10.7.4 Sumitomo Pharma Business Overview
  10.7.5 Sumitomo Pharma Recent Developments
10.8 Johnson and Johnson
  10.8.1 Johnson and Johnson Basic Information
  10.8.2 Johnson and Johnson Hormonal Therapy for Cancer Product Overview
  10.8.3 Johnson and Johnson Hormonal Therapy for Cancer Product Market Performance
  10.8.4 Johnson and Johnson Business Overview
  10.8.5 Johnson and Johnson Recent Developments
10.9 Bayer AG
  10.9.1 Bayer AG Basic Information
  10.9.2 Bayer AG Hormonal Therapy for Cancer Product Overview
  10.9.3 Bayer AG Hormonal Therapy for Cancer Product Market Performance
  10.9.4 Bayer AG Business Overview
  10.9.5 Bayer AG Recent Developments
10.10 Pfizer
  10.10.1 Pfizer Basic Information
  10.10.2 Pfizer Hormonal Therapy for Cancer Product Overview
  10.10.3 Pfizer Hormonal Therapy for Cancer Product Market Performance
  10.10.4 Pfizer Business Overview
  10.10.5 Pfizer Recent Developments
10.11 AstraZeneca
  10.11.1 AstraZeneca Basic Information
  10.11.2 AstraZeneca Hormonal Therapy for Cancer Product Overview
  10.11.3 AstraZeneca Hormonal Therapy for Cancer Product Market Performance
  10.11.4 AstraZeneca Business Overview
  10.11.5 AstraZeneca Recent Developments
10.12 Novartis
  10.12.1 Novartis Basic Information
  10.12.2 Novartis Hormonal Therapy for Cancer Product Overview
  10.12.3 Novartis Hormonal Therapy for Cancer Product Market Performance
  10.12.4 Novartis Business Overview
  10.12.5 Novartis Recent Developments
10.13 Ferring Pharmaceuticals
  10.13.1 Ferring Pharmaceuticals Basic Information
  10.13.2 Ferring Pharmaceuticals Hormonal Therapy for Cancer Product Overview
  10.13.3 Ferring Pharmaceuticals Hormonal Therapy for Cancer Product Market Performance
  10.13.4 Ferring Pharmaceuticals Business Overview
  10.13.5 Ferring Pharmaceuticals Recent Developments
10.14 Myovant Sciences
  10.14.1 Myovant Sciences Basic Information
  10.14.2 Myovant Sciences Hormonal Therapy for Cancer Product Overview
  10.14.3 Myovant Sciences Hormonal Therapy for Cancer Product Market Performance
  10.14.4 Myovant Sciences Business Overview
  10.14.5 Myovant Sciences Recent Developments

11 HORMONAL THERAPY FOR CANCER MARKET FORECAST BY REGION

11.1 Global Hormonal Therapy for Cancer Market Size Forecast
11.2 Global Hormonal Therapy for Cancer Market Forecast by Region
  11.2.1 North America Market Size Forecast by Country
  11.2.2 Europe Hormonal Therapy for Cancer Market Size Forecast by Country
  11.2.3 Asia Pacific Hormonal Therapy for Cancer Market Size Forecast by Region
  11.2.4 South America Hormonal Therapy for Cancer Market Size Forecast by Country
  11.2.5 Middle East and Africa Forecasted Sales of Hormonal Therapy for Cancer by Country

12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)

12.1 Global Hormonal Therapy for Cancer Market Forecast by Type (2026-2035)
  12.1.1 Global Forecasted Sales of Hormonal Therapy for Cancer by Type (2026-2035)
  12.1.2 Global Hormonal Therapy for Cancer Market Size Forecast by Type (2026-2035)
  12.1.3 Global Forecasted Price of Hormonal Therapy for Cancer by Type (2026-2035)
12.2 Global Hormonal Therapy for Cancer Market Forecast by Application (2026-2035)
  12.2.1 Global Hormonal Therapy for Cancer Sales (K Units) Forecast by Application
  12.2.2 Global Hormonal Therapy for Cancer Market Size (M USD) Forecast by Application (2026-2035)

13 CONCLUSION AND KEY FINDINGS
LIST OF TABLES

Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Hormonal Therapy for Cancer Market Size by Type (M USD)
Table 4. Global Hormonal Therapy for Cancer Market Size by Application
Table 5. Hormonal Therapy for Cancer Market Size Comparison by Region (M USD)
Table 6. Global Hormonal Therapy for Cancer Sales (K Units) by Manufacturers (2020-2025)
Table 7. Global Hormonal Therapy for Cancer Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Hormonal Therapy for Cancer Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Hormonal Therapy for Cancer Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hormonal Therapy for Cancer as of 2025)
Table 11. Global Market Hormonal Therapy for Cancer Average Price (USD/Unit) of Key Manufacturers (2020-2025)
Table 12. Manufacturers’ Manufacturing Sites, Areas Served
Table 13. Manufacturers’ Product Type
Table 14. Global Hormonal Therapy for Cancer Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Hormonal Therapy for Cancer Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global Hormonal Therapy for Cancer Sales by Type (K Units)
Table 27. Global Hormonal Therapy for Cancer Market Size by Type (M USD)
Table 28. Global Hormonal Therapy for Cancer Sales (K Units) by Type (2020-2025)
Table 29. Global Hormonal Therapy for Cancer Sales Market Share by Type (2020-2025)
Table 30. Global Hormonal Therapy for Cancer Market Size (M USD) by Type (2020-2025)
Table 31. Global Hormonal Therapy for Cancer Market Share by Type (2020-2025)
Table 32. Global Hormonal Therapy for Cancer Price (USD/Unit) by Type (2020-2025)
Table 33. Global Hormonal Therapy for Cancer Sales (K Units) by Application
Table 34. Global Hormonal Therapy for Cancer Market Size by Application
Table 35. Global Hormonal Therapy for Cancer Sales by Application (2020-2025) & (K Units)
Table 36. Global Hormonal Therapy for Cancer Sales Market Share by Application (2020-2025)
Table 37. Global Hormonal Therapy for Cancer Market Size by Application (2020-2025) & (M USD)
Table 38. Global Hormonal Therapy for Cancer Market Share by Application (2020-2025)
Table 39. Global Hormonal Therapy for Cancer Sales Growth Rate by Application (2020-2025)
Table 40. Global Hormonal Therapy for Cancer Sales by Region (2020-2025) & (K Units)
Table 41. Global Hormonal Therapy for Cancer Sales Market Share by Region (2020-2025)
Table 42. Global Hormonal Therapy for Cancer Market Size by Region (2020-2025) & (M USD)
Table 43. Global Hormonal Therapy for Cancer Market Size by Region (2020-2025)
Table 44. North America Hormonal Therapy for Cancer Sales by Country (2020-2025) & (K Units)
Table 45. North America Hormonal Therapy for Cancer Market Size by Country (2020-2025) & (M USD)
Table 46. Europe Hormonal Therapy for Cancer Sales by Country (2020-2025) & (K Units)
Table 47. Europe Hormonal Therapy for Cancer Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific Hormonal Therapy for Cancer Sales by Region (2020-2025) & (K Units)
Table 49. Asia Pacific Hormonal Therapy for Cancer Market Size by Region (2020-2025) & (M USD)
Table 50. South America Hormonal Therapy for Cancer Sales by Country (2020-2025) & (K Units)
Table 51. South America Hormonal Therapy for Cancer Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa Hormonal Therapy for Cancer Sales by Region (2020-2025) & (K Units)
Table 53. Middle East and Africa Hormonal Therapy for Cancer Market Size by Region (2020-2025) & (M USD)
Table 54. Global Hormonal Therapy for Cancer Production (K Units) by Region(2020-2025)
Table 55. Global Hormonal Therapy for Cancer Revenue (US$ Million) by Region (2020-2025)
Table 56. Global Hormonal Therapy for Cancer Revenue Market Share by Region (2020-2025)
Table 57. Global Hormonal Therapy for Cancer Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 58. North America Hormonal Therapy for Cancer Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 59. Europe Hormonal Therapy for Cancer Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 60. Japan Hormonal Therapy for Cancer Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 61. China Hormonal Therapy for Cancer Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 62. GlaxoSmithKline Basic Information
Table 63. GlaxoSmithKline Hormonal Therapy for Cancer Product Overview
Table 64. GlaxoSmithKline Hormonal Therapy for Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 65. GlaxoSmithKline Business Overview
Table 66. GlaxoSmithKline SWOT Analysis
Table 67. GlaxoSmithKline Recent Developments
Table 68. Jiangsu Haosen Basic Information
Table 69. Jiangsu Haosen Hormonal Therapy for Cancer Product Overview
Table 70. Jiangsu Haosen Hormonal Therapy for Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 71. Jiangsu Haosen Business Overview
Table 72. Jiangsu Haosen SWOT Analysis
Table 73. Jiangsu Haosen Recent Developments
Table 74. Sun Pharmaceutical Basic Information
Table 75. Sun Pharmaceutical Hormonal Therapy for Cancer Product Overview
Table 76. Sun Pharmaceutical Hormonal Therapy for Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 77. Sun Pharmaceutical Business Overview
Table 78. Sun Pharmaceutical SWOT Analysis
Table 79. Sun Pharmaceutical Recent Developments
Table 80. Hengrui Medical Basic Information
Table 81. Hengrui Medical Hormonal Therapy for Cancer Product Overview
Table 82. Hengrui Medical Hormonal Therapy for Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 83. Hengrui Medical Business Overview
Table 84. Hengrui Medical Recent Developments
Table 85. Dr Reddy's Laboratories Basic Information
Table 86. Dr Reddy's Laboratories Hormonal Therapy for Cancer Product Overview
Table 87. Dr Reddy's Laboratories Hormonal Therapy for Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 88. Dr Reddy's Laboratories Business Overview
Table 89. Dr Reddy's Laboratories Recent Developments
Table 90. Astellas Pharma Basic Information
Table 91. Astellas Pharma Hormonal Therapy for Cancer Product Overview
Table 92. Astellas Pharma Hormonal Therapy for Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 93. Astellas Pharma Business Overview
Table 94. Astellas Pharma Recent Developments
Table 95. Sumitomo Pharma Basic Information
Table 96. Sumitomo Pharma Hormonal Therapy for Cancer Product Overview
Table 97. Sumitomo Pharma Hormonal Therapy for Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 98. Sumitomo Pharma Business Overview
Table 99. Sumitomo Pharma Recent Developments
Table 100. Johnson and Johnson Basic Information
Table 101. Johnson and Johnson Hormonal Therapy for Cancer Product Overview
Table 102. Johnson and Johnson Hormonal Therapy for Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 103. Johnson and Johnson Business Overview
Table 104. Johnson and Johnson Recent Developments
Table 105. Bayer AG Basic Information
Table 106. Bayer AG Hormonal Therapy for Cancer Product Overview
Table 107. Bayer AG Hormonal Therapy for Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 108. Bayer AG Business Overview
Table 109. Bayer AG Recent Developments
Table 110. Pfizer Basic Information
Table 111. Pfizer Hormonal Therapy for Cancer Product Overview
Table 112. Pfizer Hormonal Therapy for Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 113. Pfizer Business Overview
Table 114. Pfizer Recent Developments
Table 115. AstraZeneca Basic Information
Table 116. AstraZeneca Hormonal Therapy for Cancer Product Overview
Table 117. AstraZeneca Hormonal Therapy for Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 118. AstraZeneca Business Overview
Table 119. AstraZeneca Recent Developments
Table 120. Novartis Basic Information
Table 121. Novartis Hormonal Therapy for Cancer Product Overview
Table 122. Novartis Hormonal Therapy for Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 123. Novartis Business Overview
Table 124. Novartis Recent Developments
Table 125. Ferring Pharmaceuticals Basic Information
Table 126. Ferring Pharmaceuticals Hormonal Therapy for Cancer Product Overview
Table 127. Ferring Pharmaceuticals Hormonal Therapy for Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 128. Ferring Pharmaceuticals Business Overview
Table 129. Ferring Pharmaceuticals Recent Developments
Table 130. Myovant Sciences Basic Information
Table 131. Myovant Sciences Hormonal Therapy for Cancer Product Overview
Table 132. Myovant Sciences Hormonal Therapy for Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 133. Myovant Sciences Business Overview
Table 134. Myovant Sciences Recent Developments
Table 135. Global Hormonal Therapy for Cancer Sales Forecast by Region (2026-2035) & (K Units)
Table 136. Global Hormonal Therapy for Cancer Market Size Forecast by Region (2026-2035) & (M USD)
Table 137. North America Hormonal Therapy for Cancer Sales Forecast by Country (2026-2035) & (K Units)
Table 138. North America Hormonal Therapy for Cancer Market Size Forecast by Country (2026-2035) & (M USD)
Table 139. Europe Hormonal Therapy for Cancer Sales Forecast by Country (2026-2035) & (K Units)
Table 140. Europe Hormonal Therapy for Cancer Market Size Forecast by Country (2026-2035) & (M USD)
Table 141. Asia Pacific Hormonal Therapy for Cancer Sales Forecast by Region (2026-2035) & (K Units)
Table 142. Asia Pacific Hormonal Therapy for Cancer Market Size Forecast by Region (2026-2035) & (M USD)
Table 143. South America Hormonal Therapy for Cancer Sales Forecast by Country (2026-2035) & (K Units)
Table 144. South America Hormonal Therapy for Cancer Market Size Forecast by Country (2026-2035) & (M USD)
Table 145. Middle East and Africa Hormonal Therapy for Cancer Sales Forecast by Country (2026-2035) & (Units)
Table 146. Middle East and Africa Hormonal Therapy for Cancer Market Size Forecast by Country (2026-2035) & (M USD)
Table 147. Global Hormonal Therapy for Cancer Sales Forecast by Type (2026-2035) & (K Units)
Table 148. Global Hormonal Therapy for Cancer Market Size Forecast by Type (2026-2035) & (M USD)
Table 149. Global Hormonal Therapy for Cancer Price Forecast by Type (2026-2035) & (USD/Unit)
Table 150. Global Hormonal Therapy for Cancer Sales (K Units) Forecast by Application (2026-2035)
Table 151. Global Hormonal Therapy for Cancer Market Size Forecast by Application (2026-2035) & (M USD)

LIST OF FIGURES

Figure 1. Product Picture of Hormonal Therapy for Cancer
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Hormonal Therapy for Cancer Market Size (M USD), 2025-2035
Figure 5. Global Hormonal Therapy for Cancer Market Size (M USD) (2020-2035)
Figure 6. Global Hormonal Therapy for Cancer Sales (K Units) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Hormonal Therapy for Cancer Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Hormonal Therapy for Cancer Product Life Cycle
Figure 13. Hormonal Therapy for Cancer Sales Share by Manufacturers in 2025
Figure 14. Global Hormonal Therapy for Cancer Revenue Share by Manufacturers in 2025
Figure 15. Hormonal Therapy for Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market Hormonal Therapy for Cancer Average Price (USD/Unit) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by Hormonal Therapy for Cancer Revenue in 2025
Figure 18. Industry Chain Map of Hormonal Therapy for Cancer
Figure 19. Global Hormonal Therapy for Cancer Market PEST Analysis
Figure 20. Global Hormonal Therapy for Cancer Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Hormonal Therapy for Cancer Market Share by Type
Figure 27. Sales Market Share of Hormonal Therapy for Cancer by Type (2020-2025)
Figure 28. Sales Market Share of Hormonal Therapy for Cancer by Type in 2025
Figure 29. Market Share of Hormonal Therapy for Cancer by Type (2020-2025)
Figure 30. Market Share of Hormonal Therapy for Cancer by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Hormonal Therapy for Cancer Market Share by Application
Figure 33. Global Hormonal Therapy for Cancer Sales Market Share by Application (2020-2025)
Figure 34. Global Hormonal Therapy for Cancer Sales Market Share by Application in 2025
Figure 35. Global Hormonal Therapy for Cancer Market Share by Application (2020-2025)
Figure 36. Global Hormonal Therapy for Cancer Market Share by Application in 2025
Figure 37. Global Hormonal Therapy for Cancer Sales Growth Rate by Application (2020-2025)
Figure 38. Global Hormonal Therapy for Cancer Sales Market Share by Region (2020-2025)
Figure 39. Global Hormonal Therapy for Cancer Market Size by Region (2020-2025)
Figure 40. North America Hormonal Therapy for Cancer Sales and Growth Rate (2020-2025) & (K Units)
Figure 41. North America Hormonal Therapy for Cancer Sales and Growth Rate (2020-2025) & (K Units)
Figure 42. North America Hormonal Therapy for Cancer Sales Market Share by Country in 2024
Figure 43. North America Hormonal Therapy for Cancer Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Hormonal Therapy for Cancer Market Size by Country in 2024
Figure 45. U.S. Hormonal Therapy for Cancer Sales and Growth Rate (2020-2025) & (K Units)
Figure 46. U.S. Hormonal Therapy for Cancer Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Hormonal Therapy for Cancer Sales (K Units) and Growth Rate (2020-2025)
Figure 48. Canada Hormonal Therapy for Cancer Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Hormonal Therapy for Cancer Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Hormonal Therapy for Cancer Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Hormonal Therapy for Cancer Sales and Growth Rate (2020-2025) & (K Units)
Figure 52. Europe Hormonal Therapy for Cancer Sales Market Share by Country in 2024
Figure 53. Europe Hormonal Therapy for Cancer Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Hormonal Therapy for Cancer Market Size by Country in 2024
Figure 55. Germany Hormonal Therapy for Cancer Sales and Growth Rate (2020-2025) & (K Units)
Figure 56. Germany Hormonal Therapy for Cancer Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Hormonal Therapy for Cancer Sales and Growth Rate (2020-2025) & (K Units)
Figure 58. France Hormonal Therapy for Cancer Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Hormonal Therapy for Cancer Sales and Growth Rate (2020-2025) & (K Units)
Figure 60. U.K. Hormonal Therapy for Cancer Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Hormonal Therapy for Cancer Sales and Growth Rate (2020-2025) & (K Units)
Figure 62. Italy Hormonal Therapy for Cancer Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Hormonal Therapy for Cancer Sales and Growth Rate (2020-2025) & (K Units)
Figure 64. Spain Hormonal Therapy for Cancer Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Hormonal Therapy for Cancer Sales and Growth Rate (K Units)
Figure 66. Asia Pacific Hormonal Therapy for Cancer Sales Market Share by Region in 2024
Figure 67. Asia Pacific Hormonal Therapy for Cancer Market Size by Region in 2024
Figure 68. China Hormonal Therapy for Cancer Sales and Growth Rate (2020-2025) & (K Units)
Figure 69. China Hormonal Therapy for Cancer Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Hormonal Therapy for Cancer Sales and Growth Rate (2020-2025) & (K Units)
Figure 71. Japan Hormonal Therapy for Cancer Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Hormonal Therapy for Cancer Sales and Growth Rate (2020-2025) & (K Units)
Figure 73. South Korea Hormonal Therapy for Cancer Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Hormonal Therapy for Cancer Sales and Growth Rate (2020-2025) & (K Units)
Figure 75. India Hormonal Therapy for Cancer Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Hormonal Therapy for Cancer Sales and Growth Rate (2020-2025) & (K Units)
Figure 77. Southeast Asia Hormonal Therapy for Cancer Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Hormonal Therapy for Cancer Sales and Growth Rate (K Units)
Figure 79. South America Hormonal Therapy for Cancer Sales Market Share by Country in 2024
Figure 80. South America Hormonal Therapy for Cancer Market Size and Growth Rate (M USD)
Figure 81. South America Hormonal Therapy for Cancer Market Size by Country in 2024
Figure 82. Brazil Hormonal Therapy for Cancer Sales and Growth Rate (2020-2025) & (K Units)
Figure 83. Brazil Hormonal Therapy for Cancer Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Hormonal Therapy for Cancer Sales and Growth Rate (2020-2025) & (K Units)
Figure 85. Argentina Hormonal Therapy for Cancer Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Hormonal Therapy for Cancer Sales and Growth Rate (2020-2025) & (K Units)
Figure 87. Columbia Hormonal Therapy for Cancer Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Hormonal Therapy for Cancer Sales and Growth Rate (K Units)
Figure 89. Middle East and Africa Hormonal Therapy for Cancer Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Hormonal Therapy for Cancer Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Hormonal Therapy for Cancer Market Size by Region in 2024
Figure 92. Saudi Arabia Hormonal Therapy for Cancer Sales and Growth Rate (2020-2025) & (K Units)
Figure 93. Saudi Arabia Hormonal Therapy for Cancer Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Hormonal Therapy for Cancer Sales and Growth Rate (2020-2025) & (K Units)
Figure 95. UAE Hormonal Therapy for Cancer Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Hormonal Therapy for Cancer Sales and Growth Rate (2020-2025) & (K Units)
Figure 97. Egypt Hormonal Therapy for Cancer Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Hormonal Therapy for Cancer Sales and Growth Rate (2020-2025) & (K Units)
Figure 99. Nigeria Hormonal Therapy for Cancer Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Hormonal Therapy for Cancer Sales and Growth Rate (2020-2025) & (K Units)
Figure 101. South Africa Hormonal Therapy for Cancer Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Hormonal Therapy for Cancer Production Market Share by Region (2020-2025)
Figure 103. North America Hormonal Therapy for Cancer Production (K Units) Growth Rate (2020-2025)
Figure 104. Europe Hormonal Therapy for Cancer Production (K Units) Growth Rate (2020-2025)
Figure 105. Japan Hormonal Therapy for Cancer Production (K Units) Growth Rate (2020-2025)
Figure 106. China Hormonal Therapy for Cancer Production (K Units) Growth Rate (2020-2025)
Figure 107. Global Hormonal Therapy for Cancer Sales Forecast by Volume (2020-2035) & (K Units)
Figure 108. Global Hormonal Therapy for Cancer Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global Hormonal Therapy for Cancer Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global Hormonal Therapy for Cancer Market Share Forecast by Type (2026-2035)
Figure 111. Global Hormonal Therapy for Cancer Sales Forecast by Application (2026-2035)
Figure 112. Global Hormonal Therapy for Cancer Market Share Forecast by Application (2026-2035)